N,N-dimethylsphingosine

a sphingosine kinase inhibitor

Also Known As:

(2R,3S,E)-2-(dimethylamino)octadec-4-ene-1,3-diol; D-erythro-N,N-dimethylsphingosine; DMS cpd; N,N-DMS; N,N-dimethyl-D-erythro-sphingosine; N,N-dimethyl-erythro-sphingosine

Networked: 35 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Amino Alcohols: 20
    - Sphingosine: 899
      - N,N-dimethylsphingosine: 35
- Alcohols: 595
  - Glycols: 38
    - Sphingosine: 899
      - N,N-dimethylsphingosine: 35
  - Amino Alcohols: 20
    - Sphingosine: 899
      - N,N-dimethylsphingosine: 35

Experts

1.	Manchester, Marianne: 2 articles (09/2015 - 01/2012)
2.	Patti, Gary J: 2 articles (09/2015 - 01/2012)
3.	Shriver, Leah P: 2 articles (09/2015 - 01/2012)
4.	Siuzdak, Gary: 2 articles (09/2015 - 01/2012)
5.	Huang, Jie-An: 2 articles (02/2013 - 12/2012)
6.	Liu, Shi-Quan: 2 articles (02/2013 - 12/2012)
7.	Qin, Meng-Bin: 2 articles (02/2013 - 12/2012)
8.	Su, Ying-Jie: 2 articles (02/2013 - 12/2012)
9.	Tang, Guo-Du: 2 articles (02/2013 - 12/2012)
10.	Melendez, Alirio J: 2 articles (03/2008 - 05/2005)

Related Diseases

1.	Reperfusion Injury 05/01/2016 - "N,N-dimethylsphingosine (DMS) has been documented to be in vitro protective against myocardial ischemia-reperfusion injury (IRI) and can recruit CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs), which may participate in the cardioprotection. " 05/01/2016 - "N,N-dimethylsphingosine attenuates myocardial ischemia-reperfusion injury by recruiting regulatory T cells through PI3K/Akt pathway in mice." 05/01/2012 - "Lai and colleagues demonstrate that pretreatment with N,N-dimethylsphingosine (DMS), a naturally occurring sphingosine derivative, provides renoprotection in ischemia/reperfusion injury. " 05/01/2012 - "Pretreatment of mice with the naturally occurring sphingosine N,N-dimethylsphingosine (DMS) was found to increase both tissue-infiltrating T effectors (Teffs, CD4(+)Foxp3(-)) and Tregs (CD4(+)Foxp3(+)) in the early phase of bilateral renal ischemia/reperfusion injury. "
2.	Myocardial Ischemia (Ischemic Heart Diseases) 05/01/2016 - "N,N-dimethylsphingosine (DMS) has been documented to be in vitro protective against myocardial ischemia-reperfusion injury (IRI) and can recruit CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs), which may participate in the cardioprotection. " 05/01/2016 - "N,N-dimethylsphingosine attenuates myocardial ischemia-reperfusion injury by recruiting regulatory T cells through PI3K/Akt pathway in mice."
3.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/01/1997 - "In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells." 08/25/1991 - "The present studies compare effects of ceramide, sphingosine, and N,N-dimethylsphingosine on epidermal growth factor (EGF) receptor phosphorylation in A431 human epidermoid carcinoma cells. " 04/05/1990 - "Our previous study suggested that N,N-dimethylsphingosine, but not unsubstituted sphingosine, could be a modulator of protein kinase C in epidermoid carcinoma A431 cells, since N,N-dimethyl-D-erythrosphingenine showed a stronger stereospecific effect on protein kinase C activity in comparison with N,N-dimethyl-L-erythrosphingenine, unsubstituted D- or L-erythrosphingenine, and gangliosides (Igarashi, Y., Hakomori, S., Toyokuni, T., Dean, B., Fujita, S., Sugimoto, M., Ogawa, T., El-Ghendy, K., and Racker, E. "
4.	Stomach Neoplasms (Stomach Cancer) 02/01/2012 - "To study the effect of the sphingosine kinase 1 (SphK1) inhibitor N,N-dimethylsphingosine (DMS) in combination with chemotherapeutic drugs (DDP, 5-Fu, MMC) on the proliferation of gastric cancer cells (SGC7901) in vitro, and to evaluate whether SphK1 inhibitors could be used as synergetic agents in chemotherapy. "
5.	Neuralgia (Stump Neuralgia) 09/01/2015 - "Recently, metabolomics revealed that the concentration of the endogenous metabolite N,N-dimethylsphingosine (DMS) is increased in the spinal cord in a model of neuropathic pain. " 10/24/2014 - "We previously showed that an increased level of the endogenous metabolite N,N-dimethylsphingosine (DMS) in the central nervous system (CNS) is sufficient to induce neuropathic pain-like behavior in rats. " 01/01/2022 - "N,N-Dimethyl-d-erythro-sphingosine (DMS), a neuropathic pain inducer, is metabolited de novo from sphingosine. " 01/22/2012 - "We show by using untargeted metabolomics that sphingomyelin-ceramide metabolism is altered in the dorsal horn of rats with neuropathic pain and that the upregulated, endogenous metabolite N,N-dimethylsphingosine induces mechanical hypersensitivity in vivo. "

Related Drugs and Biologics

1.	Sphingosine
2.	sphingosine kinase
3.	Ceramides
4.	ErbB Receptors (EGF Receptor)
5.	Protein Kinase C
6.	Gangliosides
7.	Epidermal Growth Factor (EGF)
8.	N,N-dimethylsphingenine
9.	Small Interfering RNA (siRNA)
10.	Antineoplastic Agents (Antineoplastics)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Punctures
3.	Ligation